Stories > Alpha Cognition's Business Update

Alpha Cognition's Business Update

ALS Treatment Withdrawal: FDA Concerns

Advancements in Alzheimer's and Parkinso...

Advancements in Huntington's Disease Tre...

ADvantage Therapeutics Appoints Professo...

AMX0035 for PSP: Phase 3 Trial Commences

AlzeCure's Drug Therapy Focus